Wall Street Zen Upgrades Kronos Bio (NASDAQ:KRON) to Hold

Wall Street Zen upgraded shares of Kronos Bio (NASDAQ:KRON - Free Report) to a hold rating in a research report report published on Saturday.

Kronos Bio Stock Up 1.5%

NASDAQ KRON traded up $0.01 on Friday, reaching $0.88. The company had a trading volume of 54,089 shares, compared to its average volume of 361,684. The stock has a market capitalization of $53.72 million, a PE ratio of -0.82 and a beta of 1.64. Kronos Bio has a 12 month low of $0.65 and a 12 month high of $1.60. The firm's 50 day moving average price is $0.79 and its 200 day moving average price is $0.89.

Hedge Funds Weigh In On Kronos Bio

Several institutional investors have recently added to or reduced their stakes in KRON. Kennedy Capital Management LLC boosted its position in shares of Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock valued at $142,000 after acquiring an additional 12,007 shares during the last quarter. Velan Capital Investment Management LP bought a new position in Kronos Bio during the fourth quarter valued at $33,000. GTS Securities LLC bought a new position in Kronos Bio during the fourth quarter valued at $48,000. Squarepoint Ops LLC bought a new stake in shares of Kronos Bio in the 4th quarter worth about $93,000. Finally, Deuterium Capital Management LLC bought a new stake in shares of Kronos Bio in the 1st quarter worth about $121,000. Hedge funds and other institutional investors own 64.09% of the company's stock.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.